Clinical trials: Human Immunodeficiency Virus Type 1
HIV
Switch to Maraviroc + Integrase Inhibitor
This clinical study proposes to evaluate the combination of maraviroc with an integrase strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced patients to document the efficacy, safety, and…
- Trial name
- NCT01896921
- Testing
- Switch to Maraviroc + Raltegravir or Dolutegravir
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
HIV-1 Infection
Sevelamer for Reducing Endotoxemia and Immune Activation
HIV-infected people can have an increase in inflammation in their body organs, even after taking anti-HIV medicines. Sevelamer carbonate is used to bind phosphate in dialysis patients.
- Trial name
- NCT01543958
- Testing
- Sevelamer carbonate
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection, CD4+ T Lymphocytopenia
Pyridostigmine as Immunomodulator in People Living With HIV
Human immunodeficiency virus (HIV) infection is characterized by persistent immune activation and a constant turnover of T cells. This leads to a precipitous fall in the number of T cells, as well as to an early immunosenescence.
- Conditions
- HIV-1-infection, CD4+ T Lymphocytopenia, Immune Deficiency, Immuno-senescence
- Trial name
- NCT03312244
- Testing
- Pyridostigmine Bromide
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
HIV Infections
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.
- Trial name
- NCT00013663
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
The purpose of this study is to evaluate the safety and tolerability of and immune response to an HIV DNA vaccine followed by an adenoviral vector HIV vaccine in healthy African adults at risk for HIV infection.
- Trial name
- NCT00415649
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
HIV
Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
In this research, the investigators want to see if early detection of HIV infection can be improved by testing young adults who seek urgent health care from pharmacies and healthcare facilities with symptoms similar to those…
- Trial name
- AHI (NCT01876199)
- Testing
- intense follow up
- Where
- Kenya
- Volunteers
- 522 people
- Sponsor
- University of Oxford
HIV
A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients
The purpose of this study is to evaluate the antiviral effect and durability of antiviral response (HIV-1 RNA PCR) and safety of a triple NtRTI/NsRTI therapy in antiretroviral naive patients.
- Trial name
- NCT00199121
- Testing
- Zidovudine (drug)
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
HIV-1 Infection
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
Since people started taking HIV medications, illnesses related to AIDS have decreased, but other serious illnesses like heart disease (heart attacks) and certain kinds of cancer have increased.
- Trial name
- NCT01515813
- Testing
- Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
- Where
- 9 sites in United States
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.
- Trial name
- NCT00350623
- Testing
- MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Immunomodulators on HIV-1 Reservoir
The goal of this clinical trial is to learn about the function of immunomodulators in reducing HIV reservoir. The main questions it aims to answer are: Are immunomodulators able to reduce HIV reservoirs? How do immunomodulators…
- Trial name
- NCT05598580
- Testing
- Lenalidomide, Adenosylmethionine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
HIV
SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women
The purpose of the study is to measure the drug levels in your blood and to find out whether a reduced dose (400mg) of the anti-HIV medication Efavirenz is safe when taken during pregnancy.
- Trial name
- NCT02499874
- Testing
- Efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- St Stephens Aids Trust
Human Immunodeficiency Virus - Type 1
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv) 800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in early antiretroviral (ARV)-experienced patients…
- Trial name
- ODIN (NCT00524368)
- Testing
- Darunavir (DRV), Ritonavir (rtv)
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 590 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection
IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment
IMPAACT 2015 is a cross-sectional, exploratory study that will investigate the central nervous system (CNS) reservoir in perinatally HIV-infected adolescents and young adults on effective antiretroviral therapy with…
- Trial name
- NCT03416790
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV-1
bNAbs and Anti-PD-1 in HIV
Antiretroviral therapy (ART) has significantly extended the life expectancy of people living with HIV-1 (PLWH), but it does not cure the infection.
- Trial name
- IDUNN (NCT07820813)
- Testing
- 3BNC117-LS, 10-1074-LS, Nivolumab
- Volunteers
- 90 people
- Sponsor
- Ole Schmeltz Søgaard
HIV-1 Infection, HIV Infections
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Darunavir boosted with ritonavir (darunavir/r) is a powerful protease inhibitor, able to reduce the viral load in patients infected with multi-resistant HIV strains; In vitro and in vivo studies have shown that the induction of…
- Trial name
- RADAR (NCT00849160)
- Testing
- darunavir
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infections
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing three parallel groups, to compare the immunological reconstitution and the virological efficacy…
- Trial name
- ADVANZ-3 (NCT00532168)
- Testing
- tenofovir + emtricitabine + efavirenz, tenofovir + emtricitabine + lopinavir-ritonavir, tenofovir + emtricitabine + atazanavir-ritonavir
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Juan A. Arnaiz
Human Immunodeficiency Virus
Clinical Evaluation of the Xpert® HIV-1 VL
Compare the clinical performance of the Xpert® HIV-1 VL to another FDA approved HIV-1 RNA quantitative assay using frozen and fresh specimens from known HIV-1 positive individuals.
- Trial name
- NCT02461576
- Testing
- Xpert HIV-1 VL Assay
- Volunteers
- 966 people
- Sponsor
- Cepheid
HIV Infections
A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.
To study the safety and toxicity of intranasal peptide T (D-Ala-1-peptide-T-amide) in humans, and to find out how quickly and how much of a given dose enters the bloodstream and how quickly it leaves the bloodstream.
- Trial name
- NCT00000391
- Testing
- Peptide T
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
Human Immunodeficiency Virus
Tripterygium Wilfordii Hook F (TwHF) Treatment for Immune Non-responders With HIV-1 Infection
HIV-1 infection is characterized by progressive depletion of CD4+ T cells that eventually leads to clinically significant immunodeficiency.
- Trial name
- NCT01666990
- Testing
- TwHF
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.